Navigation Links
Two New Clinical Studies Show That Limited Exposure to Blood Transfusion Significantly Increases Morbidity and Mortality After Surgery
Date:6/8/2009

Studies Advocate Blood Conservation and Appropriate Indicators for Transfusion

IRVINE, Calif., June 8 /PRNewswire-FirstCall/ -- Masimo (Nasdaq: MASI), the inventor of Pulse CO-Oximetry(TM) and Measure-Through Motion and Low-Perfusion pulse oximetry, announced today that two new studies - one conducted in patients undergoing general surgery and published in the Journal of American College of Surgeons and another conducted in patients undergoing cardiac surgery and published in the Anesthesia & Analgesia - provide additional new evidence that transfusion of just one or two units of blood significantly increases infection, pneumonia, sepsis, and mortality after surgery.(1,2) These studies suggest that transfusions and their associated risks could be "largely avoided" through implementation of better blood management techniques and "more appropriate indicators" for transfusions.

Blood transfusions may be necessary to ensure survival when a patient is bleeding heavily or has severe symptomatic anemia. However, transfusions are also given in the presence of stable anemia or when significant blood loss is expected but does not occur. These two new studies add to the growing evidence that transfusions carry life-threatening risks and urge that in the absence of benefit from transfusion, avoidance of transfusions through the use of more restrictive transfusion practices could improve patient outcomes.

In the general surgery study, researchers evaluated 125,177 patients from 121 hospitals and showed that after adjusting for all risk variables, transfusion of a single unit of blood increased 30-day mortality by 32% and morbidity (pneumonia, sepsis, or surgical site infection) by 23%. Transfusion of two units of blood increased the mortality risk by 38% and morbidity risk by 40%. In the cardiac surgery
'/>"/>

SOURCE Masimo Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Trius Announces Positive Results From Phase 2 Clinical Trial of Torezolid in Patients With Complicated Skin and Skin Structure Infections
2. Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Achieves Seventy-Five Percent Accrual
3. Merz Pharmaceuticals Announces Results of Clinical Trials with NT-201(Botulinum neurotoxin type A free from complexing proteins) at Annual Movement Disorders Society Meeting
4. Investigational Cancer Drug BSI-201 Showed Clinical Benefit in 62% of Patients with Triple-Negative Metastatic Breast Cancer and Significantly Prolonged Survival
5. Study Demonstrating Lurasidone Is Effective in Patients With Schizophrenia Published in The Journal of Clinical Psychiatry
6. PARI Pharma Reports Successful Phase Ib Clinical Results for Inhaled Liposomal Cyclosporine A and Gains FDA Orphan Drug Designation for the Prevention and Treatment of Bronchiolitis Obliterans
7. Clinical Trial Results of Pollogens TriPollar(TM) Radio Frequency Technology published in the Journal of the European Academy of Dermatology and Venereology
8. Data From Clinical Study of bioTheranostics Molecular Diagnostic Test Presented at American Society of Clinical Oncology Annual Meeting
9. Proteolix Presents Positive Clinical Data for Carfilzomib in Multiple Myeloma at the 2009 ASCO Annual Meeting
10. Neurobiological Technologies Partner, Celtic Pharma, Announces Results of XERECEPT(R) Phase 3 Clinical Program
11. Proteolix Presents Phase 1b/2 Clinical Data for Carfilzomib in Advanced Solid Tumor Patients at the 2009 ASCO Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)...   Assurex Health, a personalized medicine company ... for behavioral health and chronic pain conditions, today ... equity financing from new and existing investors, according ... Chief Executive Officer. The financing will ... Health,s GeneSight ®  products.  GeneSight,s patented ...
(Date:12/24/2014)... RALEIGH, N.C. , Dec. 23, 2014 ... plc (NASDAQ: ENDP ) (TSX: ENL), and ... announced today that they have submitted a New Drug ... U.S. Food and Drug Administration (FDA).  Buprenorphine HCl Buccal ... severe enough to require daily, around-the-clock, long-term opioid treatment ...
(Date:12/22/2014)... 22, 2014 Research and Markets ( ... "US Self-monitoring Blood Glucose Market" report to their ... This market insight focuses on the developments in ... United States . Reimbursement analysis and the effects ... for more than 73 SMBG meters have been performed, ...
Breaking Medicine Technology:Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 2Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 4Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 2Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 3Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 4Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 5US Self-monitoring Blood Glucose Market 2
... In strong collaboration with clinical research partners, Hocoma recently ... LokomatPro that offers greater system capabilities. Since the launch ... LokomatPro has established itself as an effective intervention for ... and injuries resulting in gait impairment. ...
... of a clinical research study at Sharp Memorial Hospital indicate ... functional recovery, survival and quality of life at ... for heart failure.  The study was released in the June ... of Cardiology. (Photo: http://photos.prnewswire.com/prnh/20110628/LA27443 ) ...
Cached Medicine Technology:Hocoma Launches New Version of its Established Gait Training Device LokomatPro 2New Study Shows Viability of Heart Pumps for Older Heart-Failure Patients 2New Study Shows Viability of Heart Pumps for Older Heart-Failure Patients 3
(Date:12/25/2014)... -- Overeating is common during the holidays, but there are ... says. "Don,t arrive at a party hungry. It may ... be attending a party, but deprivation leads to hunger, and ... Westchester Hospital in Mount Kisco, N.Y., said in a hospital ... day and even to have a snack before attending a ...
(Date:12/25/2014)... Dennis Thompson HealthDay ... Researchers could be closing in on a "fountain of youth" ... the health of older adults, a new study suggests. ... given a drug that targets a genetic signaling pathway linked ... Novartis report. The experimental medication, a version ...
(Date:12/25/2014)... York, New York (PRWEB) December 25, 2014 ... ) continue to move forward in a number of ... District of West Virginia, Bernstein Liebhard LLP reports. According ... Court is scheduled to convene a Joint Status Conference ... at 10:00 a.m. Parties have been directed to submit ...
(Date:12/25/2014)... 25, 2014 Plugin creators from Pixel ... A fully customizable business presentation tool made specifically for ... ProFire 5k business tool, users can now display their ... of Pixel Film Studios. “ProFire 5k gives users a ... add professionalism to a presentation” , Pixel Film Studios ...
(Date:12/25/2014)... 2014 Each year trauma accounts for ... hospital admissions across the nation (according to the ... CDC’s National Hospital Ambulatory Medical Care Survey collected ... in 2010. They estimated that there were between 3.5 ... a primary diagnosis of broken bone or fracture. ...
Breaking Medicine News(10 mins):Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 4Health News:Announcing a new ProFire 5k plugin from Pixel Film Studios for Final Cut Pro X Professionals 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 3Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 4
... continues between Israelis and Palestinians, a new University of ... inflicting on the region,s children. Palestinian and Israeli ... violence, they are also being psychologically scarred by the ... study, presented earlier this summer at the International Society ...
... intestine provide the environmental trigger that initiates and perpetuates ... to inflammatory bowel disease (IBD), a study led by ... Inflammatory bowel disease results from a loss of ... microbes that inhabit the intestine. "In this study, we ...
... as a sort of fertilizer that feeds breast ... in animal models, researchers at UCLA,s Jonsson Comprehensive ... is biologically reprogramming the immune cells that are ... from soldiers protecting the body against disease into ...
... Journal of Sexual Medicine reveals that women with low ... placebo. , Andrea Bradford, Ph.D., a psychologist at Baylor College ... University of Texas at Austin, analyzed the behaviors and symptoms ... in a large clinical trial of a drug treatment for ...
... , WEDNESDAY, Sept. 15 (HealthDay News) -- In ongoing early ... toward reducing the tell-tale inflammatory impact of the deadly bone ... drug -- called INCB018424 -- shows promise are reported in ... of Medicine . "The problem with myelofibrosis is the ...
... 14, 2010) A new investigational drug designed to penetrate ... patient for the first time ever at the Virginia G. ... a potent, targeted compound designed to selectively kill cancer cells, ... Phase I clinical trial. Pancreatic cancer is a fast-growing and ...
Cached Medicine News:Health News:Study: How Palestinian and Israeli children are psychologically scarred by exposure to war 2Health News:Study: How Palestinian and Israeli children are psychologically scarred by exposure to war 3Health News:Bacteria identified that may lead to inflammatory bowel disease in certain individuals 2Health News:Stress accelerates breast cancer progression in mice 2Health News:Stress accelerates breast cancer progression in mice 3Health News:Stress accelerates breast cancer progression in mice 4Health News:Experimental Drug Shows Promise for Bone Marrow Disorder 2Health News:Experimental Drug Shows Promise for Bone Marrow Disorder 3Health News:New investigational compound targets pancreatic cancer cells 2
... easy to operate and maintain. The units ... flexible snap-seal pockets which minimize the potential ... the water. Offered in two-, four-, and ... bags of various sizes. ThermoLine Thawing Systems ...
Conventional Digitally-Controlled Water Baths...
Dry thaws. Has an ingenious (pat. pending) massaging sytem that utilizes the tempered bladders as hands. There are no unreliable mechanical parts involved. Two pumps pressurize different segments of ...
... of two principal components. The AB5000 Console is ... pumps and can be used either in the ... The AB5000 Ventricle is a disposable blood pump ... ventricles of the heart and is designed to ...
Medicine Products: